Business Context and Reporting Period
This Form 8-K Current Report from Theriva Biologics, Inc. (TOVX) covers the event date of February 11, 2026. The filing addresses the outcome of a Special Meeting of Stockholders convened to seek approval for the issuance of up to 16,184,560 shares of common stock upon the exercise of New Warrants issued under an October 16, 2025, Warrant Inducement Agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure events rather than financial performance metrics.
Material Changes and Events
- Failed Quorum: The Special Meeting called for February 11, 2026, failed to convene because a sufficient number of shares were not present or represented by proxy to constitute a quorum.
- Consequence: The Company was unable to obtain the required Stockholder Approval for the warrant exercise proposal at this time.
- Recurring Obligation: Under the Inducement Agreement, the Company must call an additional stockholder meeting every 60 days to seek approval until the earlier of obtaining approval or the New Warrants ceasing to be outstanding, unless the investors waive this requirement.
Guidance, Outlook, and Management Commentary
Management has determined to call a new meeting of stockholders to seek approval of the warrant exercise and adjournment proposals. The Company will announce the date and time of this new meeting and will file and mail proxy materials as required. No specific financial guidance or outlook was provided in this filing.
Investor Verification Checklist
- Verify the date and time of the rescheduled Special Meeting of Stockholders.
- Review the definitive proxy statement filed on January 5, 2026, for details on the warrant exercise proposal.
- Monitor for any announcements regarding a waiver of the 60-day meeting requirement by the institutional investors.
- Confirm the status of the 16,184,560 New Warrants and their potential dilution impact if approved.